Gilead rejigs HIV immunotherapy pact, grabs a stake in biotech partner

Back in November, immunotherapy player Hookipa told investors about a twist in its big collaboration with Gilead: The biotech giant decided not to move forward with an HIV program “according to current terms,” sparking discussions about a new, revised pact.